MedTrace Logo

Post-Market Clinical Evaluation of the Zephyr Valve 5.5-LP EBV

NCT04161235 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 2

Last updated 2023-11-15

No results posted yet for this study

Summary

This is a Post-Market Evaluation of the Zephyr Valve 5.5-LP EBV to assess Treated Lobar Volume Reduction (TLVR), changes in lung function and the safety profile of the Zephyr Valve treatment with the use of at least one Zephyr Valve 5.5-LP EBV.

Conditions

  • Pulmonary Emphysema

Interventions

DEVICE

The Pulmonx Zephyr Endobronchial Valve (EBV) 5.5- LP

The Zephyr Valves are implantable bronchial valves intended to control airflow in order to improve lung function in patients with hyperinflation associated with severe emphysema and/or to reduce air leaks.

Sponsors & Collaborators

  • Pulmonx Corporation

    lead INDUSTRY

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-02-05
Primary Completion
2021-08-13
Completion
2021-12-30
FDA Device
Yes

Countries

  • Germany
  • Switzerland
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04161235 on ClinicalTrials.gov